4-ethyl-3-propyl-1H-pyrazole | 60224-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-ethyl-3-propyl-1H-pyrazole
• 英文别名: 3(5)-Propyl-4-ethyl-pyrazol；4-Ethyl-5-propylpyrazol；4-ethyl-3-propyl-1(2)H-pyrazole；4-ethyl-5-propyl-1H-pyrazole
• CAS: 60224-00-2
• 化学式: C₈H₁₄N₂
• 分子量: 138.213
• InChiKey: HLEDQWQRHQGQMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-Ethyl-5-propyl-Δ²-pyrazolin 在 sulfur 作用下， 生成 4-ethyl-3-propyl-1H-pyrazole
  参考文献：
  名称：

  Grandberg; Kost, Zhurnal Obshchei Khimii, 1958, vol. 28, p. 3071,3074; engl. Ausg. S. 3102, 3104

  摘要：

  DOI：

文献信息

• NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Boléa Christelle

  公开号：US20100144756A1

  公开（公告）日：2010-06-10

  The present invention relates to novel compounds of Formula (I), wherein X 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , Y 3 , Y 4 , M 1 , M 2 , M 3 , A m and B n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

  本发明涉及式（I）的新化合物，其中X1、X2、X3、X4、Y1、Y2、Y3、Y4、M1、M2、M3、Am和Bn如式（I）中所定义；该发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，对于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病具有用处。 该发明还涉及制药组合物以及利用这些化合物制造药物的用途，以及利用这些化合物预防和治疗mGluR4参与的疾病的用途。
• Convenient one-pot syntheses of pyrazoles from imines, a vilsmeier type reagent and hydrazine
  作者：Alan R. Katritzky、Anna Denisenko、Sergey N. Denisenko、Michael Arend

  DOI：10.1002/jhet.5570370548

  日期：2000.9

  one-pot procedure for the regioselective synthesis of pyrazoles from readily available starting materials is described. Vilsmeier type reagent 1 reacts with imines 10 (via the corresponding tautomeric secondary enamines) in tetrahydrofuran to give enaminoimine hydrochlorides 11. Nonsymmetrical imines generally react preferentially with 1 at the sterically less hindered α-position. The enaminoimine hydrochlorides

  描述了一种简单的一锅法，用于从容易获得的起始原料进行区域选择性合成吡唑。Vilsmeier型试剂1与亚胺10（通过相应的互变异构仲烯胺）在四氢呋喃中反应，得到烯氨基亚胺盐酸盐11。非对称亚胺通常在空间受阻较小的α位置优先与1反应。通过加入肼，将烯氨基亚胺盐酸盐11以中等至高产率原位转化为相应的吡唑12。
• [EN] AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES À SUBSTITUTION AMINE UTILISÉS COMME INHIBITEURS DE L'EHMT2 ET DÉRIVÉS DE CES DERNIERS
  申请人：EPIZYME INC

  公开号：WO2019079485A1

  公开（公告）日：2019-04-25

  The present disclosure relates to amine-substituted heterocyclic compounds and derivatives thereof. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) by administering an amine-substituted heterocyclic heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

  本公开涉及胺基取代的杂环化合物及其衍生物。本公开还涉及含有这些化合物的药物组合物以及通过向需要治疗的受试者施用本公开披露的胺基取代的杂环化合物或其药物组合物来治疗疾病（例如癌症）的方法。本公开还涉及利用这些化合物进行研究或其他非治疗目的的用途。
• Heteroaromatic Derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
  申请人：Boléa Christelle

  公开号：US20120329811A1

  公开（公告）日：2012-12-27

  The present invention relates to novel compounds of Formula (I), wherein X 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , Y 3 , Y 4 , M 1 , M 2 , M 3 , A m and B n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

  本发明涉及式（I）的新化合物，其中X1、X2、X3、X4、Y1、Y2、Y3、Y4、M1、M2、M3、A和Bn如式（I）中所定义的；发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，可用于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病。本发明还涉及制药组合物和使用这些化合物制造药物的用途，以及使用这些化合物预防和治疗涉及mGluR4的疾病的用途。
• NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：LegoChem Biosciences, Inc.

  公开号：US20200407350A1

  公开（公告）日：2020-12-31

  The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.